Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233472 | 0.85 | ATM (0.42) | ATMCA2CA12CA1CA9 | |
| SCHEMBL18233492 | 0.80 | MAPK1 (0.36) | ATMCA2CA12CA1CA9 | |
| SCHEMBL18223745 | 0.80 | ATM (0.37) | ATMCA2CA12CA1CA9 | |
| SCHEMBL18233473 | 0.79 | CA2 (0.39) | ATMCA2CA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL18223643 | 0.79 | NAMPT (0.34) | TRPA1 | |
| SCHEMBL18233490 | 0.78 | MAPK1 (0.46) | ATMCA2CA12CA1CA9 | |
| SCHEMBL18224013 | 0.78 | ALDH1A1 (0.47) | ATMDAGLA | |
| SCHEMBL18233488 | 0.77 | TAS2R14 (0.40) | ATMCA2CA12CA1CA9 | |
| SCHEMBL20210873 | 0.75 | ATM (0.36) | ATMCA2CA12CA1CA9 | |
| SCHEMBL18233471 | 0.74 | CA2 (0.42) | ATMCA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| EP-3101015-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| EP-3101015-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA Pharma Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | ATM 1584/4885CA2 210/4885CA12 2393/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | ATM 1584/4885CA2 210/4885CA12 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.